On August 5, 2020, Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that it has entered into an ex-US commercialization agreement with Esteve Pharmaceuticals, Inc. ("Esteve").  According to the company's annual report, filed in the U.S. District Court for the Southern District of New York on August 4, 2020, the company's first-quarter net revenue was $6.4 million.  The company's first-quarter net revenue increased 7% over the second quarter of 2020 and decreased only by about 15% over the second quarter of 2020.  The company's marketing efforts have been particularly effective during the pandemic, during periods where the number of physicians' offices that were open and the number of patients who were visiting physicians' offices plummeted.  The company's first ex-US commercialization agreement was approved by the U.S. FDA in September 2018 and the number of physicians' offices that were open during the pandemic plummeted.  The company's sales of AMPYRA increased 7% over the first quarter of this year and decreased only by about 15% over Q2 2020.  The company's continuing to invest in its digital marketing efforts.  The company announced a first ex-US commercialization agreement in the second quarter of 2020 with Esteve Pharmaceuticals.  The deal is subject to approval by the U.S. Department of Health and Human Services.  The deal is subject to court approval.  The company's continuing efforts are being evaluated by the SEC's Catherineet Abuse Unit.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.